[{"id":"26ce8bb1-3631-496d-8e89-ebb02ac16155","acronym":"ZN-c5-001","url":"https://clinicaltrials.gov/study/NCT03560531","created_at":"2021-01-18T17:31:27.066Z","updated_at":"2024-07-02T16:35:49.334Z","phase":"Phase 1/2","brief_title":"A Study of ZN-c5 in Subjects With Breast Cancer","source_id_and_acronym":"NCT03560531 - ZN-c5-001","lead_sponsor":"Zeno Alpha Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • ZN-c5"],"overall_status":"Completed","enrollment":" Enrollment 181","initiation":"Initiation: 12/08/2018","start_date":" 12/08/2018","primary_txt":" Primary completion: 04/26/2022","primary_completion_date":" 04/26/2022","study_txt":" Completion: 12/22/2022","study_completion_date":" 12/22/2022","last_update_posted":"2023-04-28"},{"id":"f08006f5-feed-4100-8437-71111a44361a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04514159","created_at":"2021-01-18T21:38:03.474Z","updated_at":"2024-07-02T16:35:56.650Z","phase":"Phase 1b","brief_title":"A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer","source_id_and_acronym":"NCT04514159","lead_sponsor":"Zeno Alpha Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • ZN-c5"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 11/12/2020","start_date":" 11/12/2020","primary_txt":" Primary completion: 10/24/2022","primary_completion_date":" 10/24/2022","study_txt":" Completion: 10/24/2022","study_completion_date":" 10/24/2022","last_update_posted":"2023-02-01"},{"id":"4db0e423-1fe1-4069-829e-2eafa35e1fd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04852419","created_at":"2021-04-21T11:53:28.889Z","updated_at":"2024-07-02T16:36:05.652Z","phase":"Phase 1b","brief_title":"A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS","source_id_and_acronym":"NCT04852419","lead_sponsor":"Zentera Therapeutics HK Limited","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZN-c5"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 05/31/2021","start_date":" 05/31/2021","primary_txt":" Primary completion: 06/23/2022","primary_completion_date":" 06/23/2022","study_txt":" Completion: 06/23/2022","study_completion_date":" 06/23/2022","last_update_posted":"2022-08-11"},{"id":"11ff5440-09c9-4d52-a589-359d2d421520","acronym":"","url":"https://clinicaltrials.gov/study/NCT04176757","created_at":"2021-01-18T20:22:15.609Z","updated_at":"2024-07-02T16:36:06.358Z","phase":"Phase 1","brief_title":"A Study of ZN-c5 in Participants With Breast Cancer","source_id_and_acronym":"NCT04176757","lead_sponsor":"Zeno Alpha Inc.","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZN-c5"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 01/03/2020","start_date":" 01/03/2020","primary_txt":" Primary completion: 04/27/2021","primary_completion_date":" 04/27/2021","study_txt":" Completion: 05/25/2021","study_completion_date":" 05/25/2021","last_update_posted":"2022-08-01"}]